Somnomed expands business and operations in Europe
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Somnomed
- US Medicare PDAC registration approved
- US Medical Expansion
- Strong Global Sales Growth continues in Second Quarter
- SomnoDent G2 FDA 510(k) cleared
- Partnership with Sleep HealthCenters
Later from Somnomed
- SomnoMed Accelerates Growth beyond Forecasts
- SomnoMed continues to break records in 4th Quarter
- Continuing High Growth in the Third Quarter
- Chairmans Letter
- Results of Institutional Entitlement Offer
Follow Somnomed into a list and get an email when it puts out news.
Follow Somnomed